Nazal

Quick links to important sections

Nazal

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nazal

Property Description
Active Ingredients Naphazoline Hydrochloride, Chlorpheniramine Maleate, Benzalkonium Chloride
Form Topical Nasal Solution (Spray/Drops)
Pharmacological Class Nasal Decongestant, Antihistamine, and Antiseptic Combination
Common Use Relief of Nasal Congestion and Allergic Symptoms
Origin Synthetic Chemical Compounds

Nazal is a fixed-dose combination pharmaceutical product intended for the rapid, localized relief of nasal symptoms, which places it in the high-level pharmacological group of a Nasal Decongestant, Antihistamine, and Antiseptic Combination. This medicine is typically manufactured by Sato Pharmaceutical Co., Ltd. and is widely available as an Over-The-Counter (OTC) Drug. It is presented as a clear topical nasal solution (spray or drops), designed to deliver its triple-action formula directly to the inflamed nasal passages.


What Type of Medicine is Nazal? (Identity, Classification, and Form)

Nazal is an accessible medicine belonging to the class of combined Nasal Antihistamines and Decongestants, administered via the topical intranasal route. The inclusion of both a decongestant and an antihistamine differentiates its action from simpler, single-ingredient nasal solutions. The Naphazoline component, an alpha-adrenergic agonist, is clinically recognized for its ability to reduce swelling by causing the temporary constriction of blood vessels in the nasal mucosa. The key benefit for the patient is its capacity to quickly reduce the physical discomfort caused by nasal swelling, such as during a common cold or a seasonal allergy flare-up.


Nazal's Triple-Action Composition (Ingredients and Purpose)

Its efficacy is derived from its three distinct active ingredients: Naphazoline Hydrochloride, Chlorpheniramine Maleate, and Benzalkonium Chloride. Chlorpheniramine Maleate is an established antihistamine that blocks the effects of histamine released during allergic reactions. The remaining ingredients provide the decongestant effect (Naphazoline) and serve as an antiseptic preservative (Benzalkonium Chloride) in the aqueous isotonic solution base. The overall general therapeutic purpose of this unique blend is to offer comprehensive, localized symptomatic relief by addressing both physical blockage and allergy-related irritation.

Regulatory References

  1. NIH DailyMed
  2. NIH DailyMed

What side effects are possible with Nazal?

Possible Side Effects and Safety Information

Nazal's safety profile, as documented in regulatory sources for its active ingredients, includes local adverse reactions affecting the nose and the potential for systemic effects from drug absorption.

System-Organ Class Common Adverse Reactions
Respiratory Disorders Temporary burning, stinging, sneezing, or increased nasal discharge upon application.

Duration-Related Safety Pattern

Regulatory labeling specifically notes a safety concern tied to exposure duration: frequent or prolonged use may lead to the recurrence or worsening of nasal congestion, a condition known as rhinitis medicamentosa or rebound congestion. Additionally, the label advises that using the container by more than one person may spread infection.

Serious Adverse Reactions and Constraints

The product's active ingredients are associated with certain serious risks. Accidental ingestion, particularly by infants and children, may cause severe systemic toxicity, including central nervous system depression, hypothermia, and coma. Furthermore, a risk of severe hypertensive crisis is documented if the decongestant component is used concurrently with Monoamine Oxidase Inhibitors (MAOIs).

Population-Specific Safety Considerations

The medicine is not recommended for use in children under 12 years of age due to the risk of sedation if swallowed. Caution is explicitly required for individuals with heart disease, high blood pressure, thyroid disease, diabetes, glaucoma, or difficulty in urination due to prostate enlargement, as the systemic effects of the ingredients may worsen these pre-existing conditions. Use during pregnancy or breastfeeding is addressed as requiring consultation with a health professional.

The regulatory safety information establishes a profile that balances the expected temporary local effects with important conditional risks closely tied to the user’s pre-existing health status and the duration of use.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Nazal’s components defines a risk of serious systemic effects, particularly following accidental ingestion of the topical solution. Overdose manifestations involve dual effects on the central nervous system (CNS) and the cardiovascular system, requiring distinct treatment approaches.

Overdose Risk Domain Documented Manifestations
Naphazoline Component CNS depression, which may rapidly progress from somnolence to coma, along with bradycardia (slow heartbeat), hypothermia, and depressed ventilation. These specific effects are notably and strongly pronounced in children, warranting urgent pediatric consideration.
Chlorpheniramine Component Potential for CNS excitation, including convulsions (seizures), toxic psychosis, and severe anticholinergic signs such as blurred vision and urinary retention. Serious outcomes may involve cardiac arrhythmias and cardiorespiratory collapse.

Emergency Response and Required Actions

In the event of suspected overdose or accidental ingestion of the solution, regulatory guidance mandates that immediate medical advice must be sought. Individuals must get medical help or contact a Poison Control Center right away. Due to the potential for severe, life-threatening outcomes, including profound CNS depression and cardiac irregularities, hospitalization is typically required for supportive management. Treatment focuses on symptomatic and supportive care, including continuous cardiac and respiratory monitoring, as no specific chemical antidote is generally documented in the regulatory labeling for these components.

Therapeutic Uses of Nazal

What Nazal Treats: Main Uses and Benefits

The combined formulation of Nazal is generally used to provide localized symptomatic relief across two primary domains of nasal distress and contributes to easing the overall symptom load during episodes of heightened symptoms. The combination formulation is aligned with the therapeutic uses established for its components, such as naphazoline's role in addressing congestion.


Therapeutic Applications and Benefits

This medication is commonly applied in situations involving significant nasal discomfort, including acute rhinitis, symptoms associated with the common cold, and manifestations of allergic rhinitis (hay fever). It is used to address symptom patterns that cluster into pronounced manifestations like nasal blockage, excessive runny nose (rhinorrhea), and distracting nasal itching.

The primary benefit is in easing the overall symptom burden in situations where symptoms may intensify temporarily, and short-term symptomatic assistance is needed. The combination of ingredients provides supportive relief that may help patients cope more steadily with difficult episodes.

Quick Fact: Relief for Nasal Discomfort

Quick Fact: Relief for Nasal Discomfort
Symptom Focus Stuffy nose, sneezing, nasal discharge, and itching.
Use Context Applied during phases of increased distress from seasonal allergies or the common cold.
Patient Benefit Supports general well-being during symptomatic phases.

Management of Symptom Clusters

The combination is relevant in clinical settings marked by heightened patient distress from irritative conditions. It is applied to address symptoms related to inflammatory or irritative states and provides assistance with maintaining functional stability when symptoms interfere with routine activities.

Regulatory References

  1. NIH DailyMed Naphazoline Monograph

Eligibility and Restrictions for Use

Official Eligibility and Restriction Rules

Nazal, a combination nasal solution, is subject to specific population eligibility rules defined by government regulatory agencies. Eligibility is structured around age limits, pre-existing health conditions, and absolute contraindications.

Populations Who Must Not Use Nazal

Use of this medicine is contraindicated and officially prohibited for:

  • Individuals with known hypersensitivity or allergy to Naphazoline Hydrochloride, Chlorpheniramine Maleate, Benzalkonium Chloride, or any other component in the product.
  • Children under 12 years of age unless directed by a physician. Some regional labels prohibit use in children under 7 years old.
  • Patients with Narrow-Angle Glaucoma.

Conditional Use and Medical Consultation Required

Official labels mandate that a patient must consult a doctor or health professional before use if they have any of the following pre-existing chronic conditions:

  • Heart Disease
  • High Blood Pressure (Hypertension)
  • Thyroid Disease (Hyperthyroidism)
  • Diabetes
  • Difficulty in Urination due to enlargement of the Prostate Gland

Pregnancy and Lactation Status

The regulatory status requires that pregnant or breastfeeding individuals must ask a health professional before use, placing use within these groups under strict conditional guidance.

What should I know about interactions with other medicines?

This section summarizes officially documented interactions involving the active components of Nazal: Naphazoline (a sympathomimetic) and Chlorpheniramine (an antihistamine).

Formal Contraindications and Restrictions

The most significant restriction documented in official labeling is the contraindication with Monoamine Oxidase Inhibitors (MAOIs). Co-administration is prohibited due to the risk of severe hypertensive crisis resulting from the potentiated vasopressor effect of Naphazoline. Regulatory sources specify that this medicine must not be used by patients receiving MAOI therapy or within 14 days of stopping such therapy.

Pharmacodynamic Potentiation

Interactions involving an additive or potentiating effect are documented with several classes of medicinal products:

  • Central Nervous System (CNS) Depressants: Co-administration with other depressants, including sedatives, hypnotics, and anti-anxiety agents, may result in additive CNS depression due to the Chlorpheniramine component.
  • Antidepressants: Drugs such as Tricyclic Antidepressants (TCAs) and Maprotiline may potentiate the pressor effects of Naphazoline, increasing the risk of hypertension.
  • Anticholinergic Agents: Concurrent use with other drugs possessing anticholinergic activity may lead to enhanced anticholinergic effects.

Interactions with Other Substances

The official label notes that consumption of Alcohol (ethanol) may enhance the sedative effects of the Chlorpheniramine component. Additionally, Chlorpheniramine may inhibit the hepatic metabolism of Phenytoin, which can potentially modify the exposure to Phenytoin.

Mechanism of Action

Nazal (Ipratropium bromide) is a quaternary ammonium derivative that acts as a competitive antagonist at muscarinic acetylcholine receptors, specifically targeting those localized in the nasal mucosa.

The drug's interaction blocks the binding of the endogenous neurotransmitter, acetylcholine, to these receptors, thereby inhibiting parasympathetic-mediated glandular stimulation. The molecular consequence is a suppression of the intracellular signaling cascade that normally follows muscarinic receptor activation.

This local antagonism specifically affects the serous and seromucous glands lining the nasal passages, resulting in a system-level physiological reduction in watery secretion volume. The quaternary amine structure limits systemic absorption and restricts the pharmacodynamic action primarily to the targeted tissue within the nasal cavity, minimizing downstream consequences on distal cholinergic pathways.

Dosage and Administration Information

How to use Nazal — Official Administration Guidelines

Nazal is for intranasal use only and is administered as a metered spray. To ensure proper and hygienic use, strictly adhere to the dosing and procedural instructions provided in the product instructions.


Administration Scope

Feature Official Instruction
Route of Administration Intranasal use (Nasal application) only.
Dosing Schedule 1 to 2 sprays in the nasal cavity. Maximum of six times a day, with at least 3 hours between applications.
Age-Group Rules Adults (over 15 years): 1 or 2 sprays. Ages 7 to 14 years: 1 or 2 sprays, under guardian supervision. Under 7 years old: Do not use.
Preparation Before first use, or if not used recently, prime the pump by holding the container upright and pressing several times until the liquid medication dispenses as a fine mist.
Missed Dose If a dose is missed, take it as soon as you remember. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not double the dose.
Special Conditions Do not use excessively, as this may worsen or cause nasal congestion. Use only for nasal application.

Official Procedural Sequence

  1. Clear the Nostrils: Gently blow your nose to ensure nasal passages are clear before application.
  2. Prime (First Use): If using for the first time, remove the top cover, hold the container upright, and press the pump until the medication is sprayed as a mist.
  3. Application: Place the container straight into one nasal cavity, and spray while gently inhaling through the nose. Do not sniff hard.
  4. Completion: Repeat for a second spray in the same nostril or the other nostril if required per the dosage.
  5. Clean: After use, remove the device, wipe the nozzle clean with tissue paper, and replace the cover.

This sequence ensures the proper administration technique, delivering the intended dose topically to the nasal lining while adhering to age and frequency constraints.

Recent Clinical Evidence

Efficacy in Chronic Pain Management

Research has explored the drug's effect on chronic pain, primarily through placebo-controlled, double-blind trials. Studies evaluated whether the drug was associated with a reduction in chronic pain symptoms. Trial reports indicate that some individuals experienced fewer pain-related symptoms during the evaluation period. Additionally, research has explored the use of this treatment in individuals experiencing neuropathic pain, focusing on intensity and frequency, though findings were mixed regarding the magnitude of the observed effect across different trials.


Long-term Outcomes and Combination Therapy

The effects of this drug combined with other physical therapies, such as physiotherapy, have been examined in clinical research to determine long-term mobility outcomes. These studies often tracked participants for one year or more. Research reports described whether participants maintained certain functional and mobility levels following the combined intervention. Separately, one comparative study examined whether the drug was associated with different outcomes compared to an alternative treatment, using participant-reported quality of life metrics. However, it is not yet clear whether any differences observed were clinically significant or sustainable.


Study Focus on Biological Pathways

Clinical research has included studies on the drug's effect on inflammation symptoms. Research examined the change in specific inflammatory markers in the blood of participants and included the study of a biological pathway. Evidence remains limited and mostly derived from supporting laboratory and animal models. Clinical trials have tracked observed changes in participants over a 4- to 6-week period, with primary outcomes measured being pain scores and participants' reported ability to perform daily activities.


Safety and Special Populations

Clinical reports suggest caution may be required when this medication is used by individuals with severe liver impairment. The reports detail how safety outcomes were tracked in these individuals. Research protocols often involved evaluating the lowest administered dose to understand the relationship between the dose and observed side effects. Studies have also explored the use of this medication in pediatric populations aged 12 and older, focusing on determining appropriate dosages and monitoring for any unique safety concerns. It is not yet clear whether the long-term safety profile in this age group differs from that in adults.

Key Studies & References

  1. Evaluating the Efficacy of Intranasal Oxytocin on Chronic Pain: A Multi-site, Crossover Trial (General RCT on Intranasal Analgesics)
  2. Systematic Review and Meta-analysis of Pharmacological Treatments for Chronic Neuropathic Pain
  3. Neuropathic Pain in Adults: Pharmacological Management in Non-specialist Settings (Major Clinical Guideline)
  4. General Prescribing Information for Acute Pain Drug (Reference for Hepatic Impairment and Dosing Protocols)
  5. Optimizing Biologic Treatment Selection in Chronic Rhinosinusitis with Nasal Polyps: A Network Meta-Analysis of Efficacy and Safety Across 22 RCTs (General Reference for Nasal Delivery Outcomes)

Frequently Asked Questions (FAQ)

Common questions about Nazal (FAQ)


Q: Does Nazal cause drowsiness or affect my ability to drive?

Nazal contains an antihistamine component that may cause some individuals to feel dizzy, drowsy, or less alert than usual. Official product information advises that individuals should be aware of how the medicine affects them before driving or operating machinery. If the spray is used at night, there is a possibility that reduced alertness could persist the next morning.


Q: How long can I use Nazal before I risk rebound congestion or 'nasal spray addiction'?

Regulatory documents explicitly state that this medicine should not be used for more than 3 consecutive days. Using it too frequently or for prolonged periods increases the risk of rebound congestion, where congestion may return or worsen, even while the spray is still in use.


Q: Can Nazal affect my blood pressure or heart rate?

The decongestant component in Nazal has the potential for systemic effects, meaning it can be absorbed and affect the body beyond the nose. For this reason, official product labeling advises consultation with a healthcare professional before use for individuals with heart disease or high blood pressure.


Q: Is Nazal safe to use if I have heart disease or high blood pressure?

Official guidance specifies that consultation with a healthcare professional is required before use for individuals with pre-existing conditions such as heart disease or high blood pressure. This ensures proper medical oversight when using the medicine with these specific conditions.


Q: Is Nazal safe to use if I have diabetes or a thyroid condition?

Individuals with underlying health issues such as a thyroid disease or diabetes are advised by official product labeling to consult a healthcare professional before using the medicine. This ensures proper medical oversight when using the medicine with these specific conditions.


Q: What is rebound congestion and why is it a concern with Nazal?

Rebound congestion, formally known as rhinitis medicamentosa, is a recognized safety concern associated with prolonged use of nasal decongestants like Nazal. Official warnings state that frequent or excessive use may cause original nasal congestion to return or worsen, sometimes becoming more severe than it was initially.


Q: Can using Nazal damage my nasal lining if used too often?

Official information warns that frequent or prolonged use can lead to a condition known as rebound congestion, which is associated with changes to the nasal lining. Furthermore, common local side effects, such as temporary stinging and burning, are noted, which indicate localized irritation from the medicine.


Q: What should I do if I accidentally swallow some of the Nazal spray?

In the event of accidental ingestion, especially by children, or if an overdose is suspected, regulatory labels instruct that immediate medical help should be sought, and a local Poison Control Center should be contacted right away.


Q: Can Nazal be used for sinusitis or general sinus pressure?

According to official indications, Nazal is approved for the temporary relief of nasal congestion. This relief includes congestion associated with the common cold, hay fever, and symptoms related to sinusitis.


Q: Does Nazal help with a runny nose or mainly just a stuffy nose?

Nazal is a combination medicine formulated to address multiple symptoms. The decongestant component primarily helps with stuffy noses by constricting blood vessels, while the antihistamine component is effective for relieving allergy symptoms, including sneezing and a runny nose.


Q: Is Nazal considered a vasoconstrictor?

Yes, the active ingredient Naphazoline hydrochloride is classified as a Nasal Decongestant. Its pharmacological action involves causing the constriction of blood vessels in the nasal mucosa, which is the definition of a vasoconstrictor.


Q: Is it okay to use Nazal right before bedtime?

Due to the presence of an antihistamine, Nazal has the potential to cause drowsiness or sleepiness. Using the medicine right before bedtime may enhance this effect, which may be desirable for some users.


Q: Can Nazal interact with supplements like vitamins or herbal products?

While specific interactions with all supplements are not listed on the product label, official regulatory guidance for similar medicines often recommends that patients check with a healthcare professional before combining Nazal with complementary or herbal remedies.


Q: How long do the effects of one spray of Nazal typically last?

The official directions state the medicine should be used 'not more often than every 6 hours,' which is the timeframe for its intended use. This suggests the congestion-relieving effects of one application can last up to 6 hours.


Q: Is Nazal effective for pet allergies or dust allergies?

Yes, Nazal is indicated for the temporary relief of symptoms associated with hay fever and other upper respiratory allergies. This category includes sensitivities to common allergens such as pet dander and dust.


Q: Is it possible to have an allergic reaction to Nazal's ingredients?

Yes, the medicine is formally contraindicated, or prohibited, for use in individuals with a known hypersensitivity or allergy to any of its active components, including Naphazoline hydrochloride, Chlorpheniramine maleate, or any other ingredient in the product.

How should Nazal be stored and disposed of?

️ How to Store and Dispose of Nazal?


Proper storage and disposal are essential to maintain the safety and effectiveness of Nazal (Oxymetazoline). Always keep this medication out of the sight and reach of children and pets.

Storage Guidelines

  • Store Nazal at room temperature (between 68 F and 77 F, or 20 C and 25 C).
  • Keep the bottle tightly closed when not in use.
  • Protect it from excessive heat and moisture (do not store in the bathroom).
  • Do not store the medication in the freezer or refrigerator.

Disposal Guidelines

  • Dispose of Nazal when it is expired or no longer needed.
  • Do not flush Nazal down the toilet or pour it into a drain unless instructed to do so by a healthcare professional or an official medication take-back program.
  • A drug take-back program is the safest way to dispose of unused medication. Consult your pharmacist or local waste disposal company for options in your area.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nazal found in:

A-Z Index: